December 11, 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of HematologyNovember 10, 2006
FDA approves MIRAPEX for the treatment of moderate-to-severe primary Restless Legs SyndromeOctober 31, 2006
Boehringer Ingelheim launches PROUD study to explore possible disease-modifying effect of pramipexoleOctober 12, 2006
Boehringer Ingelheim Announces Agreement to Acquire Zantac® from Johnson & JohnsonAugust 24, 2006
Pramipexole safe and effective in treating restless legs syndrome, study showsAugust 23, 2006
New study of depressive symptoms in Parkinson's disease patients shows positive results for Mirapex
Full Prescribing Information
June 19, 2006
New National Campaign Gives Americans “BREATHING ROOM” to Learn about COPD — Chronic Bronchitis and Emphysema — Program Designed to Increase Awareness of COPD, An Under-Recognized Disease in the United StatesJune 19, 2006
Multiple new studies strongly support efficacy of pramipexole in treating restless legs syndrome
Full
Prescribing Information
June 9, 2006
Boehringer Ingelheim Provides Update on Aptivus® (tipranavir)
Clinical Trial in Treatment-Naïve HIV-Infected Patients
Full
Prescribing Information
May 21, 2006
Spiriva improved lung function in COPD patients of African descent
Full
Prescribing Information
February 23, 2006
Boehringer Ingelheim Provides Update on Study Arms of Aptivus® (tipranavir) Clinical Trial in Treatment-Naïve HIV-Infected Patients
Full
Prescribing Information
January 24, 2006
Ingelheim Launches Industry’s Largest Thromboembolic Disease Clinical Trial Program to Date